ResearcherAscentage Pharma Group Inc. (United States)Active in the last 2 years

Yifan Zhai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1672-2262; OpenAlex author ID A5021773274. Sources: ClinicalTrials.gov.

Their work

Papers: 1
Trials: 1
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2021: 1 trial · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 1

A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2025.102364 ↗

Trials 1

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma Study chair NCT04643405 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Miaoyan Wei · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Wei Wang · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Chen Liu · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Xianjun Yu · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Xiaowu Xu · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Jin Xu · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗
Si Shi · 1 shared paper, 2025 · strength 0.20
- Paper A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metasta… DOI 10.1016/j.xcrm.2025.102364 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.